Answers are grounded in this paper and cite their sources.
Patients with high-risk resected gastrointestinal stromal tumors (GIST) receiving adjuvant imatinib have improved recurrence-free survival (RFS), however whether a complete cytocidal effect exists is unknown. We investigated this using a normalized recurrence timeline measured from end of oncologic treatment (EOOT), defined as the later of resection or end of adjuvant therapy.
No takes yet. Share an insight, caveat, or question.
Sutton et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: